Editorial Board
Revision as of 22:43, 27 October 2022 by Warner-admin (talk | contribs)
Our editorial board is comprised of clinical and pharmacological experts, organized primarily by disease focus. Most disease types now have expert representation, but we are still looking for potential section or page editors. If you are interested, please feel free to contact us with any questions or inquiries, at [email protected].
Editor-in-Chief
 |
Peter C. Yang, MD Boston, MA  Hem_Onc
|
Dr. Yang is board certified in Hematology and Medical Oncology; he practices at an academically affiliated institution in Massachusetts. |
Deputy Editor
 |
Jeremy L. Warner, MD, MS, FAMIA, FASCO Brown University Providence, RI Hemoncwarner |
Dr. Warner is board certified in Hematology, Medical Oncology, and Clinical Informatics; he practices at the Lifespan Cancer Institute. He is an Associate Professor (appointment pending) of Medicine and Public Health at Brown University. He is the Director of the Brown/Lifespan Center for Cancer Bioinformatics and Data Science. |
Associate Editors
| Evidence-based Oncology | ||
|---|---|---|
 |
Bishal Gyawali, MD, PhD Queen’s University Kingston, Canada oncology_bg
|
Dr. Gyawali is an Associate Professor in the Departments of Oncology and Public Health Sciences at Queen’s University, Kingston, Canada and an Ontario Institute for Clinical Research-Scientist II. He is an advocate of a "cancer groundshot", a term he coined to imply that investment should be made on proven high-value interventions in cancer care that are easy to implement globally and are affordable. |
| Cancer Registries | ||
 |
Mary Mesnard, BS, CTR |
Ms. Mesnard is a senior study director at Westat and was formerly with the State of Maryland's central cancer registry. |
| Pediatric Hematology/Oncology | ||
 |
Wayne H. Liang, MD, MS, FAMIA Atlanta, GA WayneLiangMD |
Dr. Liang is board certified in Pediatrics, Pediatric Hematology-Oncology, and Clinical Informatics; he practices at Children’s Healthcare of Atlanta. He is an Assistant Professor of Pediatrics at Emory University. |
Section Editors
| Breast Oncology | ||
|---|---|---|
 |
H. Deepika Fernandes, MD, FACP Tempe, AZ |
Dr. Fernandes is board certified in Medical Oncology and Hematology; she practices at the HonorHealth Virginia G. Piper Cancer Care Network. |
| Dermatologic Oncology | ||
 |
Elizabeth Buchbinder, MD Boston, MA |
Dr. Buchbinder is board certified in Medical Oncology; she practices at the Dana-Farber Cancer Institute. She is an instructor at Harvard Medical School. |
| Endocrine Oncology | ||
| Unfilled | If you are interested in this role, please contact us at [email protected]. | |
| Gastrointestinal Oncology, Intestinal | ||
| Unfilled | If you are interested in this role, please contact us at [email protected]. | |
| Gastrointestinal Oncology, Extraintestinal | ||
 |
Eric I. Marks, MD Boston, MA |
Dr. Marks is board certified in Medical Oncology; he practices at Boston Medical Center and is an Assistant Professor of Medicine at Boston University School of Medicine. |
| Genitourinary Oncology | ||
 |
Ali Raza Khaki, MD Palo Alto, CA |
Dr. Khaki is board certified in Hematology and Medical Oncology; he practices at Stanford Health Care. He is a a Clinical Assistant Professor of Oncology at Stanford University School of Medicine. |
| Gynecologic Oncology | ||
 |
Alaina J. Brown, MD, MPH Nashville, TN |
Dr. Brown is board certified in Gynecologic Oncology and Obstetrics and Gynecology; she practices at the Vanderbilt-Ingram Cancer Center. She is an Assistant Professor of Obstetrics and Gynecology at Vanderbilt University. |
| Head & Neck Cancer | ||
 |
Michael K. Gibson, MD, PhD, FACP Nashville, TN mgibson21212 |
Dr. Gibson is board certified in Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an associate professor at Vanderbilt University. |
| Mesothelioma | ||
 |
Marjorie G. Zauderer, MD New York, NY MGZauderer
|
Dr. Zauderer is board certified in Medical Oncology; she is co-director of the mesothelioma program at Memorial Sloan Kettering Cancer Center. |
| Neuro-Oncology | ||
 |
Seema Nagpal, MD Palo Alto, CA |
Dr. Nagpal is board certified in Neurology and UCNS certified in Neuro-Oncology; she practices at Stanford Health Care. She is a clinical associate professor at Stanford University |
| Sarcoma | ||
 |
Elizabeth J. Davis, MD Nashville, TN ejdavis25
|
Dr. Davis is board certified in Medical Oncology; she practices at the Vanderbilt-Ingram Cancer Center and is the medical director of the Clinical Trials Office. She is an associate professor at Vanderbilt University. |
| Thoracic Oncology | ||
 |
Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN AmitKulkarniMD
|
Dr. Kulkarni is board certified in Internal Medicine and board eligible in Medical Oncology; he practices and is an Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation at the University of Minnesota. |
| Acute Leukemias | ||
 |
Martin W. Schoen, MD, MPH Saint Louis University St. Louis, MO |
Dr. Schoen is board certified in Internal Medicine and board eligible in Hematology and Medical Oncology; he practices at the Saint Louis Veterans Affairs Medical Center. He is an assistant professor at Saint Louis University. |
| Myeloproliferative Neoplasms and Myelodysplastic Syndromes | ||
 |
Sanjay R. Mohan, MD, MSCI Nashville, TN |
Dr. Mohan is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University. |
| Aggressive Lymphomas & Lymphoproliferative disorders | ||
 |
Tarsheen K. Sethi, MD, MSCI Yale University New Haven, CT tarsheen2
|
Dr. Sethi is board certified in Hematology and Medical Oncology; she practices at the Smilow Cancer Hospital at Yale New Haven. She is an assistant professor at Yale University. |
| Indolent Lymphomas | ||
 |
Sanjai Sharma, MD Visalia, CA |
Dr. Sharma is board certified in Hematology and Medical Oncology; he practices at the Sequoia Regional Cancer Center. |
| Plasma Cell Dyscrasias | ||
 |
Andrew J. Cowan, MD Seattle, WA andrewcowanmd |
Dr. Cowan is board certified in Hematology and Medical Oncology; he practices at the Seattle Cancer Care Alliance. He is an assistant professor at the University of Washington. |
| T-cell and NK-cell neoplasms | ||
 |
Bhagirathbhai Dholaria, MBBS Nashville, TN |
Dr. Dholaria is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University. |
| Histiocyte Disorders | ||
 |
Gaurav Goyal, MBBS UAB Birmingham, AL GauravGoyalMD
|
Dr. Goyal is board certified in Hematology and Medical Oncology; he practices at UAB Medicine. He is an assistant professor at UAB (The University of Alabama at Birmingham). |
| Pediatric Leukemia & Lymphoma | ||
 |
David Noyd, MD, MPH Oklahoma City, OK |
Dr. Noyd is board certified in Pediatrics and board eligible in Pediatric Hematology-Oncology; he practices at OU Health. He is an Assistant Professor of Pediatrics at the University of Oklahoma. |
| Pediatric Neuro-Oncology & Solid Tumors | ||
 |
Nikki M. Wood, DO Kansas City, MO WoodNikkiM |
Dr. Wood is board certified in Pediatrics and Pediatric Hematology-Oncology; she practices at Children's Mercy Kansas City. She is an Assistant Professor of Pediatrics at the University of Missouri-Kansas City School of Medicine. |
| Immuno-Oncology | ||
 |
Leyre Zubiri, MD, PhD Boston, MA |
Dr. Zubiri is a research fellow in hematology/oncology at Massachusetts General Hospital. |
| Transplant | ||
 |
Talal Hilal, MD University of Mississippi Jackson, MS THilalMD
|
Dr. Hilal is board certified in Hematology and Medical Oncology; he practices at University of Mississippi Medical Center. He is an assistant professor at the University of Mississippi. |
| Classical Hematology | ||
 |
Benjamin Tillman, MD Nashville, TN |
Dr. Tillman is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University. |
Page Editors
- Jon Arnason, MD (Beth Israel Deaconess Medical Center, Boston, MA)
- Karine A. Darbinyan, MD (Altru Cancer Center, Grand Forks, ND)
- Teja Ganta, MD (Icahn School of Medicine at Mount Sinai, Manhattan, NY)
- Laura S. Graham, MD (University of Colorado, Anschutz Medical Campus, Aurora, CO)
- Ashwin Kishtagari, MD (Vanderbilt University, Nashville, TN)
- Shalin Kothari, MD (Yale University, New Haven, CT)
- Mary L. Kwok, MD, FACP (Seattle Cancer Care Alliance, Seattle, WA)
- Eric I. Marks, MD (Boston University, Boston, MA)
- Francesca Montanari, MD (Yale University, New Haven, CT)
- Ryan Nguyen, DO (University of Illinois at Chicago, IL)
- Samuel M. Rubinstein, MD (University of North Carolina, Chapel Hill, NC)
- Nishi N. Shah, MD (Montefiore Medical Center, Bronx, NY)
- Eric K. Singhi, MD (MD Anderson Cancer Center, Houston, TX)
- Risa L. Wong, MD (UPMC, Pittsburgh, PA)
COI Disclosures
Please see our conflict of interest page for more details. Disclosures here are for COI within 12 months of the date of disclosure unless otherwise noted.
| Name | Research funding (to institution) | Other (honoraria, travel support, significant ownership interests, etc.) | Date of disclosure |
|---|---|---|---|
| Jon Arnason | Nothing to disclose | Nothing to disclose | 2021-11-10 |
| Alaina J. Brown | NIH | Nothing to disclose | 2022-08-03 |
| Elizabeth Buchbinder | NIH; Trial funding: Eli Lilly, Novartis, Partners therapeutics, Genentech, BVD | Consulting/Advisory Board: Novartis, Apexigen, Shionogi, BMS, Instilbio, Nektar | 2022-05-08 |
| Andrew Cowan | Abbvie, Nektar, Harpoon, Janssen, Adaptive, Sanofi, BMS, Celgene | Consultancy: Abbvie, BMS, Secura Bio, EUSA, GSK | 2022-04-26 |
| Karine A. Darbinyan | Nothing to disclose | Nothing to disclose | 2022-08-03 |
| Elizabeth J. Davis | Research funding: NIH/NCI; ECOG Trial funding: Karyopharm, BMS, Incyte, Actuate, Bio Atla, Top Alliance Biosciences, Genentech |
Consulting/Advisory Board: Deciphera | 2021-11-10 |
| Bhagirathbhai Dholaria | Research funding: Janssen, Angiocrine, Pfizer, Poseida, MEI, Orcabio, Wugen, Allovir | Consulting/Advisory Board: Jazz, Gamida Cell, MJH BioScience, Arivan Research, BEAM therapeutics, Janssen, Atheneum; Study steering committee: Gamida Cell | 2022-08-04 |
| H. Deepika Fernandes | Nothing to disclose | Nothing to disclose | 2021-04-03 |
| Teja Ganta | Nothing to disclose | Nothing to disclose | 2022-08-05 |
| Michael K. Gibson | Nothing to disclose | Nothing to disclose | 2021-11-15 |
| Gaurav Goyal | Nothing to disclose | Royalties from UpToDate and consulting fees from 2nd.MD | 2022-08-02 |
| Laura Graham | Nothing to disclose | Nothing to disclose | 2022-08-04 |
| Bishal Gyawali | Nothing to disclose | Consulting/Advisory Board: Vivio Health | 2022-08-24 |
| Talal Hilal | Nothing to disclose | Consulting/Advisory Board: Incyte Editorship: Springer |
2022-08-22 |
| Ali R. Khaki | Nothing to disclose | Consulting/Advisory Board: Seagen/Astellas Travel: BCAN; SABCS Honoraria: Onclive CME |
2021-11-11 |
| Ashwin Kishtagari | Nothing to disclose | Consulting/Advisory Board: CTI BioPharma | 2022-08-03 |
| Mary L. Kwok | Nothing to disclose | Nothing to disclose | 2022-04-21 |
| Wayne H. Liang | Nothing to disclose | Consulting/Advisory Board: Westat | 2021-11-10 |
| Eric Marks | Nothing to disclose | Nothing to disclose | 2022-04-25 |
| Sanjay R. Mohan | Trial funding: Incyte, Karyopharm, Novartis, Taiho | Nothing to disclose | 2022-04-22 |
| Seema Nagpal | Trial funding: Agios, PharmAbcine, Insightec, Berg, Inovio | Consulting/Advisory Board: EnClear, SeaGen, Novocure Steering Committee, Nurix, Biocept Steering Committee; Guidelines: NCCN CNS committee, ARS-AUC CNS committee, ASTRO Brain metastases guideline committee | 2022-04-22 |
| Ryan Nguyen | Nothing to disclose | Nothing to disclose | 2022-08-04 |
| David Noyd | Nothing to disclose | Nothing to disclose | 2022-08-31 |
| Samuel R. Rubinstein | Nothing to disclose | Consulting/Advisory Board: Sanofi, Roche, Janssen, EUSA pharma | 2022-08-03 |
| Martin Schoen | St. Louis Veterans Affairs Medical Center, Congressionally Directed Medical Research Program | Consulting/Advisory Board: Doximity, Pfizer | 2022-08-05 |
| Sanjai Sharma | Nothing to disclose | Nothing to disclose | 2022-08-04 |
| Eric K. Singhi | Nothing to disclose | Nothing to disclose | 2022-08-02 |
| Benjamin F. Tillman | Nothing to disclose | Nothing to disclose | 2021-10-13 |
| Jeremy L. Warner | AACR; NIH; Vanderbilt University | Travel: AACR; ASCO Ownership: HemOnc.org Consulting/Advisory Board: Westat, MelaxTech, Roche, Flatiron Health; Editorship: ASCO |
2022-05-08 |
| Risa L. Wong | Nothing to disclose | Consulting/Advisory Board: Voluntis | 2022-08-03 |
| Nikki M. Wood | Nothing to disclose | Consulting/Advisory Board: Westat | 2021-11-10 |
| Peter C. Yang | Nothing to disclose | Ownership: HemOnc.org Stock: Merck, Pfizer |
2022-04-22 |
| Marjorie Zauderer | Memorial Sloan Kettering receives research funding from the Department of Defense, the National Institutes of Health, Precog, GlaxoSmithKline, Epizyme, Polaris, Sellas Life Sciences, Bristol Myers Squibb, Millenium/Takeda, Curis, and Atara for research conducted by Dr. Zauderer. | In the last 3 years, Dr. Zauderer has received consulting fees from Curis, Ikena, Takeda, GlaxoSmithKline, Aldeyra Therapeutics, Novocure, and Atara and honoraria for CME content from PER, Medscape, Research to Practice, Medical Learning Institute and OncLive. Dr. Zauderer serves as Chair of the Board of Directors of the Mesothelioma Applied Research Foundation, uncompensated. | 2022-10-20 |